Why Charles River Laboratories International, Inc. (CRL) Stock Rose 5.1% on Oct 20, 2026
What happened
Charles River Laboratories rallied 5.11% to $315.36, driven by a bullish research report from Citrini Research highlighting CRL as a major beneficiary of AI-driven drug discovery and increased demand for preclinical laboratory services (per Seeking Alpha and Yahoo Finance). The move also reflects momentum from CRL's late-September Investor Day, where management raised fiscal 2026 EPS guidance to $11.15–$11.45 and issued strong 2030 targets, prompting analyst price-target raises into the $310–$345 range.
CRL earnings scheduled for November 4, 2026 (date not yet confirmed); consensus EPS estimate is $2.97. Watch for management commentary on AI adoption trends and 2027 outlook.
Frequently asked questions
Why did Charles River Laboratories International, Inc. (CRL) stock rise on Oct 20, 2026?
Charles River Laboratories rallied 5.11% to $315.36, driven by a bullish research report from Citrini Research highlighting CRL as a major beneficiary of AI-driven drug discovery and increased demand for preclinical laboratory services (per Seeking Alpha and Yahoo Finance). The move also reflects momentum from CRL's late-September Investor Day, where management raised fiscal 2026 EPS guidance to $11.15–$11.45 and issued strong 2030 targets, prompting analyst price-target raises into the $310–$345 range.
How much did CRL stock rise on Oct 20, 2026?
CRL rose 5.1% during the Oct 20, 2026 trading session.